MA39485A - Méthode de traitement de la dépression et du trouble dépressif majeur - Google Patents

Méthode de traitement de la dépression et du trouble dépressif majeur

Info

Publication number
MA39485A
MA39485A MA039485A MA39485A MA39485A MA 39485 A MA39485 A MA 39485A MA 039485 A MA039485 A MA 039485A MA 39485 A MA39485 A MA 39485A MA 39485 A MA39485 A MA 39485A
Authority
MA
Morocco
Prior art keywords
depressive disorder
major depressive
treating depression
depression
treating
Prior art date
Application number
MA039485A
Other languages
English (en)
Inventor
Jarlath Ffrench-Mullen
Eric Lai
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of MA39485A publication Critical patent/MA39485A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/112Disease subtyping, staging or classification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/16Primer sets for multiplex assays

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA039485A 2014-03-05 2015-03-04 Méthode de traitement de la dépression et du trouble dépressif majeur MA39485A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461948529P 2014-03-05 2014-03-05
US201462061417P 2014-10-08 2014-10-08

Publications (1)

Publication Number Publication Date
MA39485A true MA39485A (fr) 2015-09-11

Family

ID=54055831

Family Applications (1)

Application Number Title Priority Date Filing Date
MA039485A MA39485A (fr) 2014-03-05 2015-03-04 Méthode de traitement de la dépression et du trouble dépressif majeur

Country Status (12)

Country Link
US (1) US20170137880A1 (fr)
EP (1) EP3114239A4 (fr)
JP (1) JP2017512204A (fr)
KR (1) KR20160127126A (fr)
CN (1) CN106536751A (fr)
AU (1) AU2015227296A1 (fr)
CA (1) CA2940683A1 (fr)
IL (1) IL247379A0 (fr)
MA (1) MA39485A (fr)
MX (1) MX2016011384A (fr)
RU (1) RU2016138574A (fr)
WO (1) WO2015134585A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017087735A1 (fr) * 2015-11-18 2017-05-26 Millennium Pharmaceuticals, Inc. Procédé de traitement de la maladie de crohn
US20190216803A1 (en) 2017-03-30 2019-07-18 Rundle Research, LLC Methods of treating depression with vortioxetine
HRP20211241T1 (hr) * 2017-03-30 2021-11-12 Rundle Research, LLC Vortioksetin i inhibitori mao za liječenje depresije
EP3909600A1 (fr) * 2020-05-12 2021-11-17 International Centre For Genetic Engineering And Biotechnology - ICGEB Protéine emid2 en tant que traitement anticancéreux

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2044043T5 (pl) * 2006-06-16 2022-05-02 H. Lundbeck A/S Bromowodorek 1-[2-(2,4-dimetylofenylosulfanylo)fenylo]piperazyny jako związek o połączonym działaniu wychwytu zwrotnego serotoniny i działaniu na 5-ht3 i 5-ht1a do leczenia upośledzenia funckji poznawczych
CA2712075A1 (fr) * 2008-01-17 2009-07-23 Suregene Llc Marqueurs genetiques de maladie mentale
WO2012031008A2 (fr) * 2010-08-31 2012-03-08 The General Hospital Corporation Matières biologiques liées au cancer dans des microvésicules
US20130274133A1 (en) * 2010-10-01 2013-10-17 Rigshospitalet Genetic variations in the interleukin-6 receptor gene as predictors of the response of patients to treatment with interleukin-6 receptor inhibitors
US9243464B2 (en) * 2011-02-10 2016-01-26 Baker Hughes Incorporated Flow control device and methods for using same
WO2012109565A1 (fr) * 2011-02-10 2012-08-16 Neurotherics, Llc Identification génétique de réponse à des médicaments antidépresseurs
RU2622082C2 (ru) * 2011-11-14 2017-06-09 Нестек С.А. Анализы и способы выбора режима лечения пациента с депрессией

Also Published As

Publication number Publication date
CN106536751A (zh) 2017-03-22
KR20160127126A (ko) 2016-11-02
MX2016011384A (es) 2017-05-01
JP2017512204A (ja) 2017-05-18
CA2940683A1 (fr) 2015-09-11
IL247379A0 (en) 2016-11-30
AU2015227296A1 (en) 2016-09-08
EP3114239A1 (fr) 2017-01-11
US20170137880A1 (en) 2017-05-18
EP3114239A4 (fr) 2017-10-11
RU2016138574A3 (fr) 2018-10-12
RU2016138574A (ru) 2018-04-06
WO2015134585A1 (fr) 2015-09-11

Similar Documents

Publication Publication Date Title
IL290994A (en) Methods of diagnosing and treating conduct disorder
IL246678A0 (en) Azepane derivatives and methods of treating hepatitis b infections
EP3500289A4 (fr) Procédés de traitement de la trachéobronchomalacie
EP3463350A4 (fr) Méthode de traitement de la fibrose hépatique
EP3341080A4 (fr) Méthode de traitement du cancer
EP3288383A4 (fr) Méthodes de traitement du cancer
EP3380121A4 (fr) Méthode de traitement de troubles oculaires
IL249071B (en) Bleaching and shive reduction process for non-wood fibers
EP3423488A4 (fr) Méthodes de traitement du cancer
EP3391873A4 (fr) Procédé et ensemble de traitement capillaire
EP3375440A4 (fr) Méthode de traitement de la mucosite
EP3522934A4 (fr) Compositions et méthode pour le traitement de la rénopathie
EP3389634A4 (fr) Méthodes de traitement du cancer
EP3405203A4 (fr) Méthodes de traitement du cancer
EP3630732A4 (fr) Méthode et molécules
PL3393468T3 (pl) Metody leczenia niedoboru odporności
EP3440112A4 (fr) Méthodes de traitement du cancer
DK3233071T3 (da) Fremgangsmåde til behandling eller forebyggelse af Ras-medierede sygdomme
EP3313417A4 (fr) Méthodes de traitement de troubles auto-immuns et allo-immuns
EP3448365A4 (fr) Méthode de traitement de la constipation
IL257764B (en) Methods for treatment of diseases
EP3331499A4 (fr) Composition et méthode de traitement de troubles métaboliques
EP3389652A4 (fr) Méthodes de traitement du cancer
PL3520308T3 (pl) Aparatura i sposób rozmieszczania podramek
MA41462A (fr) Méthode de traitement de maladies